RhumbLine Advisers
TWST icon

RhumbLine Advisers’s Twist Bioscience TWST Stock Holding History

RhumbLine Advisers’s Portfolio TWST Stock Details TWST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.2M Buy
99,388
+9,344
+10% +$608K 0.01% 1083
2026
Q1 		$4.28M Sell
90,044
-1,078
-1% -$48.3K ﹤0.01% 1475
2025
Q4 		$2.89M Sell
91,122
-4,085
-4% -$127K ﹤0.01% 1676
2025
Q3 		$2.68M Sell
95,207
-4,154
-4% -$126K ﹤0.01% 1747
2025
Q2 		$3.66M Buy
99,361
+3,397
+4% +$117K ﹤0.01% 1576
2025
Q1 		$3.77M Buy
95,964
+4,571
+5% +$206K ﹤0.01% 1496
2024
Q4 		$4.25M Buy
91,393
+2,339
+3% +$106K ﹤0.01% 1510
2024
Q3 		$4.02M Sell
89,054
-3,843
-4% -$183K ﹤0.01% 1538
2024
Q2 		$4.58M Sell
92,897
-8,070
-8% -$329K ﹤0.01% 1443
2024
Q1 		$3.46M Buy
100,967
+3,673
+4% +$133K ﹤0.01% 1610
2023
Q4 		$3.59M Sell
97,294
-250
-0.3% -$5.78K ﹤0.01% 1605
2023
Q3 		$1.98M Sell
97,544
-16,572
-15% -$364K ﹤0.01% 1866
2023
Q2 		$2.33M Buy
114,116
+32,127
+39% +$481K ﹤0.01% 1812
2023
Q1 		$1.24M Buy
81,989
+1,472
+2% +$32.5K ﹤0.01% 2034
2022
Q4 		$1.92M Buy
80,517
+2,562
+3% +$74.3K ﹤0.01% 1808
2022
Q3 		$2.75M Buy
77,955
+5,113
+7% +$217K ﹤0.01% 1597
2022
Q2 		$2.55M Buy
72,842
+16,434
+29% +$582K ﹤0.01% 1640
2022
Q1 		$2.79M Buy
56,408
+6,110
+12% +$339K ﹤0.01% 1641
2021
Q4 		$3.89M Sell
50,298
-633
-1% -$65K ﹤0.01% 1520
2021
Q3 		$5.45M Buy
50,931
+1,183
+2% +$135K 0.01% 1314
2021
Q2 		$6.63M Sell
49,748
-1,510
-3% -$176K 0.01% 1273
2021
Q1 		$6.35M Buy
51,258
+10,290
+25% +$1.56M 0.01% 1270
2020
Q4 		$5.79M Buy
40,968
+1,910
+5% +$212K 0.01% 1271
2020
Q3 		$2.97M Sell
39,058
-5,472
-12% -$341K ﹤0.01% 1470
2020
Q2 		$2.02M Buy
44,530
+12,120
+37% +$435K ﹤0.01% 1715
2020
Q1 		$991K Buy
32,410
+6,757
+26% +$182K ﹤0.01% 1885
2019
Q4 		$539K Buy
25,653
+628
+3% +$14.7K ﹤0.01% 2329
2019
Q3 		$598K Buy
25,025
+140
+0.6% +$4.07K ﹤0.01% 2256
2019
Q2 		$722K Buy
+24,885
New +$658K ﹤0.01% 2210

Other funds holding TWST

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

RhumbLine Advisers's TWST Position: Q2 2026 in Review

RhumbLine Advisers increased its Twist Bioscience (TWST) stake by 10% in Q2 2026, buying an estimated $608K and bringing the position to 99,388 shares worth $10.2M. The position accounts for 0.01% of the portfolio, ranked #1083.

RhumbLine Advisers first reported a position in TWST in Q2 2019 and has held it in 29 quarters since. 337 funds tracked by Wall St. Rank hold TWST as of Q2 2026.

  • RhumbLine Advisers held 99,388 shares of Twist Bioscience worth $10.2M as of Q2 2026.
  • RhumbLine Advisers bought 9,344 Twist Bioscience shares in Q2 2026, an estimated $608K.
  • Twist Bioscience made up 0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #1083 holding.
  • RhumbLine Advisers first reported a position in Twist Bioscience in Q2 2019 and has held it in 29 quarters since.
  • 337 funds tracked by Wall St. Rank held Twist Bioscience as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.